| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO, & Head of R&D | Jun 22, 2015 | Option Exercise | $78.87 | 38 | 2,997 | 32,675 | Jun 23, 2015, 10:41 AM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | SVP, Finance & Business Ops. | Jun 22, 2015 | Option Exercise | $78.87 | 56 | 4,417 | 24,446 | Jun 23, 2015, 10:33 AM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Williams Glen | SVP, Technical Operations | Jun 22, 2015 | Option Exercise | $78.87 | 56 | 4,417 | 26,024 | Jun 23, 2015, 10:31 AM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Williams Glen | SVP, Technical Operations | Jun 08, 2015 | Sale | $145.61 | 25,832 | 3,761,315 | 38,884 | Jun 09, 2015, 06:13 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Williams Glen | SVP, Technical Operations | May 06, 2015 | Sale | $127.28 | 3,332 | 424,098 | 2,134 | May 08, 2015, 05:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO & Head of R&D | Apr 27, 2015 | Option Exercise | $55.85 | 20,000 | 1,117,000 | 15,637 | Apr 29, 2015, 05:28 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO & Head of R&D | Apr 21, 2015 | Sale | $108.00 | 10,000 | 1,080,000 | 5,637 | Apr 23, 2015, 07:28 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO & Head of R&D | Apr 15, 2015 | Sale | $72.87 | 20,000 | 1,457,400 | 25,637 | Apr 17, 2015, 05:14 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Williams Glen | SVP, Technical Operations | Apr 07, 2015 | Option Exercise | $68.31 | 5,623 | 384,116 | 3,237 | Apr 09, 2015, 05:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Williams Glen | SVP, Technical Operations | Apr 08, 2015 | Sale | $73.52 | 79,726 | 5,861,417 | 40,331 | Apr 09, 2015, 05:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO & Head of R&D | Apr 06, 2015 | Option Exercise | $61.11 | 49,048 | 2,997,499 | 45,140 | Apr 08, 2015, 06:35 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | SVP, Finance and Business Ops. | Mar 11, 2015 | Sale | $71.98 | 15,086 | 1,085,902 | 7,890 | Mar 13, 2015, 05:49 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Feb 17, 2015 | Sale | $64.32 | 84,594 | 5,440,888 | 42,297 | Feb 19, 2015, 04:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BAKER FELIX | Director | Jan 07, 2015 | Buy | $94.19 | 1,000,000 | 94,190,002 | 9,184,771 | Jan 09, 2015, 05:29 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Baker Brothers Life Sciences LP | Director | Jan 07, 2015 | Buy | $94.19 | 1,000,000 | 94,190,002 | 9,184,771 | Jan 09, 2015, 05:28 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | Group Vice President, Finance | Dec 29, 2014 | Sale | $55.15 | 12,200 | 672,841 | 6,404 | Dec 30, 2014, 04:49 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Dec 17, 2014 | Option Exercise | $52.06 | 100,000 | 5,206,335 | 51,031 | Dec 19, 2014, 05:56 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Oct 28, 2014 | Sale | $45.11 | 5,000 | 225,550 | 2,500 | Oct 30, 2014, 08:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Oct 30, 2014 | Option Exercise | $44.56 | 45,808 | 2,041,066 | 22,904 | Oct 30, 2014, 08:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | EVP, Medical & Reg. Strategy | Sep 19, 2014 | Sale | $36.98 | 1,580 | 58,436 | 1,352 | Sep 19, 2014, 05:56 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | EVP, Medical & Reg. Strategy | Sep 16, 2014 | Sale | $36.87 | 18,758 | 691,607 | 9,941 | Sep 18, 2014, 05:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | EVP, Medical & Reg. Strategy | Sep 17, 2014 | Sale | $36.89 | 8,400 | 309,918 | 4,762 | Sep 18, 2014, 05:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO & Head of R&D | Sep 02, 2014 | Sale | $46.57 | 20,000 | 931,404 | 35,595 | Sep 04, 2014, 05:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | Group Vice President, Finance | Jun 30, 2014 | Option Exercise | $54.89 | 112 | 6,148 | 304 | Jul 02, 2014, 05:56 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO & Head of R&D | Jun 30, 2014 | Option Exercise | $54.89 | 71 | 3,897 | 25,595 | Jul 02, 2014, 05:56 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | EVP, Medical & Reg. Strategy | Jun 30, 2014 | Option Exercise | $54.89 | 103 | 5,654 | 562 | Jul 02, 2014, 05:56 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Williams Glen | SVP, Technical Operations | Jun 30, 2014 | Option Exercise | $54.89 | 117 | 6,422 | 383 | Jul 02, 2014, 05:49 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Williams Glen | SVP, Technical Operations | Jun 25, 2014 | Sale | $79.10 | 1,400 | 110,734 | 966 | Jun 26, 2014, 04:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quart Barry D | Director | Jun 20, 2014 | Option Exercise | $62.50 | 2,750 | 171,875 | 1,375 | Jun 24, 2014, 05:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Baker Bros. Investments II, L.P. | Director | Jun 20, 2014 | Option Exercise | $60.45 | 29,750 | 1,798,388 | 8,184,771 | Jun 24, 2014, 04:12 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quart Barry D | Director | Jun 17, 2014 | Option Exercise | $56.98 | 2,000 | 113,950 | 1,000 | Jun 19, 2014, 05:28 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quart Barry D | Director | Jun 12, 2014 | Option Exercise | $53.15 | 2,000 | 106,310 | 1,000 | Jun 16, 2014, 06:56 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | EVP, Medical & Reg. Strategy | Jun 11, 2014 | Option Exercise | $43.83 | 43,194 | 1,893,273 | 22,056 | Jun 12, 2014, 05:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | May 16, 2014 | Sale | $41.82 | 19,854 | 830,278 | 9,927 | May 20, 2014, 04:42 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | 14159, L.P. | Director | Apr 23, 2014 | Option Exercise | $65.10 | 56,000 | 3,645,600 | 8,180,521 | Apr 25, 2014, 08:04 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO & Head of R&D | Apr 01, 2014 | Option Exercise | $0.95 | 10,000 | 9,500 | 25,524 | Apr 03, 2014, 09:56 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO & Head of R&D | Apr 01, 2014 | Sale | $47.75 | 40,000 | 1,910,191 | 35,524 | Apr 03, 2014, 05:56 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | Group Vice President, Finance | Mar 12, 2014 | Sale | $57.03 | 15,340 | 874,916 | 7,862 | Mar 14, 2014, 04:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | 14159, L.P. | Director | Mar 06, 2014 | Buy | $105.75 | 375,000 | 39,656,250 | 8,172,521 | Mar 07, 2014, 05:54 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BAKER FELIX | Director | Mar 06, 2014 | Buy | $105.75 | 375,000 | 39,656,250 | 8,172,521 | Mar 07, 2014, 05:53 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Feb 18, 2014 | Sale | $51.84 | 19,854 | 1,029,244 | 9,927 | Feb 20, 2014, 04:14 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Jan 28, 2014 | Sale | $45.38 | 102,658 | 4,658,919 | 52,360 | Jan 30, 2014, 05:42 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Jan 29, 2014 | Option Exercise | $45.75 | 101,942 | 4,663,371 | 52,002 | Jan 30, 2014, 05:42 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | EVP, CMO & Head of R&D | Dec 31, 2013 | Option Exercise | $36.30 | 192 | 6,970 | 15,524 | Jan 02, 2014, 07:14 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Williams Glen | SVP, Technical Operations | Dec 31, 2013 | Option Exercise | $36.30 | 132 | 4,792 | 266 | Jan 02, 2014, 07:14 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | EVP, Medical & Reg. Strategy | Dec 31, 2013 | Option Exercise | $36.30 | 192 | 6,970 | 459 | Jan 02, 2014, 07:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | Group Vice President, Finance | Dec 31, 2013 | Option Exercise | $36.30 | 192 | 6,970 | 192 | Jan 02, 2014, 07:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | SVP,Medical&Regulatory Affairs | Dec 03, 2013 | Sale | $60.52 | 7,000 | 423,649 | 680 | Dec 04, 2013, 05:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | SVP,Medical&Regulatory Affairs | Dec 02, 2013 | Option Exercise | $8.73 | 7,000 | 61,110 | 7,267 | Dec 04, 2013, 05:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Nov 18, 2013 | Sale | $28.39 | 19,854 | 563,733 | 9,927 | Nov 20, 2013, 04:56 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | SVP,Medical&Regulatory Affairs | Nov 01, 2013 | Sale | $29.35 | 14,000 | 410,863 | 7,267 | Nov 04, 2013, 05:35 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | SVP,Medical&Regulatory Affairs | Oct 01, 2013 | Sale | $36.52 | 14,000 | 511,313 | 7,267 | Oct 03, 2013, 04:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BAKER FELIX | Director | Sep 25, 2013 | Buy | $56.63 | 1,050,000 | 59,461,501 | 7,806,552 | Sep 27, 2013, 04:08 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BAKER JULIAN | Director | Sep 25, 2013 | Buy | $56.63 | 4,200,000 | 237,846,004 | 7,806,552 | Sep 27, 2013, 04:08 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Aug 21, 2013 | Option Exercise | $35.09 | 13,362 | 468,939 | 6,681 | Aug 22, 2013, 05:28 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Aug 20, 2013 | Option Exercise | $27.34 | 15,600 | 426,457 | 7,800 | Aug 22, 2013, 05:28 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Aug 16, 2013 | Sale | $24.59 | 8,600 | 211,431 | 4,300 | Aug 20, 2013, 05:35 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Jul 25, 2013 | Sale | $16.35 | 46,626 | 762,186 | 32,946 | Jul 29, 2013, 06:35 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Jul 26, 2013 | Sale | $28.66 | 121,584 | 3,484,532 | 70,425 | Jul 29, 2013, 06:35 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Jul 29, 2013 | Sale | $25.45 | 31,790 | 809,214 | 16,926 | Jul 29, 2013, 06:35 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | Vice President, Finance | Jul 16, 2013 | Sale | $48.26 | 2,029 | 97,920 | 0 | Jul 17, 2013, 04:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | Vice President, Finance | Jul 15, 2013 | Sale | $8.95 | 3,019 | 27,027 | 2,524 | Jul 17, 2013, 04:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Jul 11, 2013 | Sale | $24.38 | 26,474 | 645,436 | 13,237 | Jul 15, 2013, 04:35 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | SVP,Medical&Regulatory Affairs | Jun 28, 2013 | Option Exercise | $35.68 | 267 | 9,527 | 267 | Jul 01, 2013, 05:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Williams Glen | SVP, Technical Operations | Jun 28, 2013 | Option Exercise | $35.68 | 134 | 4,781 | 134 | Jul 01, 2013, 05:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | SVP, Chief Medical Officer | Jun 28, 2013 | Option Exercise | $35.68 | 297 | 10,597 | 15,332 | Jul 01, 2013, 05:07 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Jun 11, 2013 | Sale | $20.92 | 59,296 | 1,240,472 | 30,679 | Jun 13, 2013, 05:28 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Jun 12, 2013 | Option Exercise | $20.85 | 80,704 | 1,682,832 | 41,383 | Jun 13, 2013, 05:28 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Apr 05, 2013 | Option Exercise | $25.53 | 19,820 | 506,005 | 10,941 | Apr 09, 2013, 04:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Apr 08, 2013 | Option Exercise | $25.22 | 43,390 | 1,094,296 | 22,726 | Apr 09, 2013, 04:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Apr 03, 2013 | Sale | $26.36 | 32,928 | 867,868 | 17,495 | Apr 05, 2013, 02:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Apr 04, 2013 | Sale | $25.61 | 43,862 | 1,123,149 | 22,962 | Apr 05, 2013, 02:21 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | SVP,Medical&Regulatory Affairs | Apr 01, 2013 | Sale | $27.63 | 8,832 | 244,026 | 4,416 | Apr 03, 2013, 10:21 AM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | SVP, Product Development | Mar 01, 2013 | Sale | $25.86 | 8,834 | 228,413 | 4,417 | Mar 06, 2013, 06:00 AM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Feb 20, 2013 | Sale | $25.23 | 49,216 | 1,241,882 | 25,639 | Feb 22, 2013, 05:05 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Feb 21, 2013 | Option Exercise | $24.99 | 90,784 | 2,268,238 | 46,423 | Feb 22, 2013, 05:05 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | SVP, Product Development | Feb 01, 2013 | Sale | $24.35 | 8,834 | 215,088 | 4,417 | Feb 05, 2013, 05:35 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | SVP, Chief Medical Officer | Jan 18, 2013 | Option Exercise | $25.52 | 18,894 | 482,080 | 24,482 | Jan 23, 2013, 05:05 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | SVP, Chief Medical Officer | Jan 17, 2013 | Option Exercise | $25.47 | 400 | 10,190 | 15,235 | Jan 18, 2013, 05:00 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | SVP, Chief Medical Officer | Jan 16, 2013 | Option Exercise | $47.03 | 5,706 | 268,360 | 20,388 | Jan 18, 2013, 05:00 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Jan 16, 2013 | Option Exercise | $25.41 | 19,854 | 504,490 | 9,927 | Jan 18, 2013, 04:50 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | TISCH THOMAS J | Director | Jan 09, 2013 | Buy | $47.53 | 21,039 | 999,984 | 373,560 | Jan 15, 2013, 05:48 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BAKER FELIX | Director | Jan 04, 2013 | Buy | $47.53 | 859,720 | 40,862,491 | 6,782,215 | Jan 08, 2013, 05:41 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Baker Brothers Life Sciences LP | Director | Jan 04, 2013 | Buy | $47.53 | 859,720 | 40,862,491 | 6,782,215 | Jan 08, 2013, 05:40 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Goldberg Mark Alan | SVP, Product Development | Jan 02, 2013 | Option Exercise | $24.24 | 8,834 | 214,092 | 4,417 | Jan 04, 2013, 04:30 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | Vice President, Finance | Dec 19, 2012 | Sale | $23.44 | 8,000 | 187,505 | 4,000 | Dec 21, 2012, 03:45 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Dec 13, 2012 | Sale | $23.30 | 28,800 | 671,150 | 15,431 | Dec 17, 2012, 07:15 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Dec 14, 2012 | Option Exercise | $23.12 | 26,562 | 614,246 | 14,312 | Dec 17, 2012, 07:15 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Dec 17, 2012 | Sale | $23.89 | 64,638 | 1,544,041 | 33,350 | Dec 17, 2012, 07:15 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Dec 04, 2012 | Option Exercise | $25.15 | 46,000 | 1,156,700 | 24,031 | Dec 06, 2012, 05:05 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Dec 05, 2012 | Option Exercise | $24.53 | 24,000 | 588,655 | 13,031 | Dec 06, 2012, 05:05 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Nov 30, 2012 | Option Exercise | $24.91 | 10,000 | 249,076 | 6,031 | Dec 04, 2012, 05:20 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Dec 03, 2012 | Option Exercise | $25.18 | 60,000 | 1,510,992 | 31,031 | Dec 04, 2012, 05:20 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | Vice President, Finance | Oct 17, 2012 | Option Exercise | $25.49 | 8,000 | 203,920 | 4,000 | Oct 19, 2012, 05:10 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | BOESS CARSTEN | SVP, Chief Financial Officer | Oct 16, 2012 | Sale | $25.92 | 19,854 | 514,526 | 9,927 | Oct 18, 2012, 05:40 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Heberlig Chris | Vice President, Finance | Sep 04, 2012 | Sale | $25.02 | 2,000 | 50,050 | 1,000 | Sep 06, 2012, 05:00 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Aug 31, 2012 | Option Exercise | $25.41 | 30,374 | 771,946 | 16,218 | Sep 05, 2012, 05:30 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Patel Sanj K | President & CEO | Sep 04, 2012 | Option Exercise | $25.15 | 109,626 | 2,757,445 | 55,844 | Sep 05, 2012, 05:30 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | SVP, Chief Medical Officer | Jul 27, 2012 | Option Exercise | $25.59 | 12,800 | 327,581 | 26,435 | Jul 30, 2012, 04:50 PM | |
| GEVA | SYNAGEVA BIOPHARMA CORP | Quinn Anthony | SVP, Chief Medical Officer | Jul 26, 2012 | Option Exercise | $25.47 | 2,200 | 56,045 | 21,135 | Jul 30, 2012, 04:50 PM |
Menu